Trial reportFrontiers in immunology2018
Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced
Trial report in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- The soldiers needed to be awakened: Tumor-infiltrating immune cells.Frontiers in genetics · 2022Pooled it
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Review
- Beyond TLS Presence: A Functional Framework Integrating Maturity, Location, and Immune Context.Cancers · 2026Review
- Tumor infiltrating B cells and tertiary lymphoid structures in pancreatic cancer prognosis and therapy.iScience · 2026Review
- CD4Cancer biology & medicine · 2026Review
- B-cells in breast cancer: current insights and challenges.Frontiers in oncology · 2026Review
- Combination detection of IgG- and IgA-related autoantibodies for the early diagnosis of gastric cancer.Cancer biomarkers : section A of Disease markers · 2025Article
- The landscape of research on B cell and immunotherapy in solid tumors over the past 20 years.Discover oncology · 2025Article
- Tumor-infiltrating B cells in non-small cell lung cancer: current insights and future directions.Cancer cell international · 2025Review
- B cells and tertiary lymphoid structures in tumors: immunity cycle, clinical impact, and therapeutic applications.Theranostics · 2025Review
- Tertiary lymphoid structures: exploring opportunities to improve immunotherapy in ovarian cancer.Frontiers in immunology · 2025Review
- Automated Quantification of Tertiary Lymphoid Structures in Human Tumor Samples Using Immunofluorescence and AI-Powered Analysis Pipeline.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Characterization of TrkB autoantibodies reveals an agonist binding region in breast cancer.American journal of cancer research · 2025Article
- The Dual Role of B Cells in the Tumor Microenvironment: Implications for Cancer Immunology and Therapy.International journal of molecular sciences · 2024Review
- Tertiary lymphoid structures in anticancer immunity.Nature reviews. Cancer · 2024Review
- B cell-based therapy produces antibodies that inhibit glioblastoma growth.The Journal of clinical investigation · 2024Article
- Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2024Review
- DNA-delivered monoclonal antibodies targeting the p53 R175H mutant epitope inhibit tumor development in mice.Genes & diseases · 2024Article
- Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant.Journal of hematology & oncology · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An important role for tumor infiltrating B lymphocytes (TIL-B) in the immune response to cancer is emerging; however, very little is known about the antigen specificity of antibodies produced
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.